Entorhinal cortex beta-amyloid load in individuals with mild cognitive impairment

Related Experiment Video

Updated: Oct 19, 2026

Abbiategrasso Brain Bank Protocol for Collecting, Processing and Characterizing Aging Brains
12:28

Abbiategrasso Brain Bank Protocol for Collecting, Processing and Characterizing Aging Brains

Published on: June 3, 2020

E J Mufson1, E Y Chen, E J Cochran

  • 1Department of Neurological Sciences, Rush Alzheimer's Disease Center, Chicago, Illinois, 60612, USA.

Experimental Neurology
|July 23, 1999
PubMed

Insights

Beta-amyloid deposition in the entorhinal cortex is linked to cognitive decline. While Alzheimer's patients show high levels, mild cognitive impairment cases have intermediate amounts, suggesting other factors contribute to cognitive impairment.

Area of Science:

  • Neuroscience
  • Neuropathology
  • Geriatrics

Background:

  • Beta-amyloid deposition in the entorhinal cortex is implicated in mild cognitive impairment (MCI) and Alzheimer's disease (AD).
  • Understanding the role of beta-amyloid in cognitive decline is crucial for developing effective interventions.

Purpose of the Study:

  • To investigate the association between beta-amyloid deposition in the entorhinal cortex and cognitive status in elderly individuals.
  • To compare beta-amyloid load in the entorhinal cortex among individuals with no cognitive impairment (NCI), MCI, and AD.

Main Methods:

  • Immunohistochemical quantification of beta-amyloid in entorhinal cortex tissue from aged clergy.
  • Clinical assessment of cognitive status (MCI, NCI, AD) and Mini-Mental State Examination (MMSE).
  • Statistical analysis including ANOVA, multiple comparisons, and Spearman rank correlation.

Main Results:

  • Beta-amyloid staining was detected in NCI, MCI, and AD groups, with varying patterns and loads.
  • A significant difference in mean beta-amyloid load was observed across the groups (NCI < MCI < AD).
  • MCI individuals had intermediate beta-amyloid loads, not statistically distinct from NCI or AD, and a trend of decreasing MMSE with increasing amyloid load.

Conclusions:

  • Beta-amyloid deposition in the entorhinal cortex is present in individuals with and without cognitive impairment.
  • While beta-amyloid load increases with cognitive decline, it is not the sole determinant of cognitive impairment in the elderly.
  • Further research is needed to elucidate the complex interplay of factors contributing to cognitive impairment.

More Related Videos

The 4 Mountains Test: A Short Test of Spatial Memory with High Sensitivity for the Diagnosis of Pre-dementia Alzheimer's Disease06:23

The 4 Mountains Test: A Short Test of Spatial Memory with High Sensitivity for the Diagnosis of Pre-dementia Alzheimer's Disease

Published on: October 13, 2016

Related Concept Videos

Alzheimer Disease ll: Pathophysiology01:23

Alzheimer Disease ll: Pathophysiology

Alzheimer disease involves structural changes in the brain that begin long before symptoms appear. The most distinctive features are extracellular neuritic plaques and intracellular neurofibrillary tangles.Neuritic plaques form in the cerebral cortex and around blood vessels. These plaques contain a dense core of beta-amyloid (Aβ)—a toxic protein fragment that clumps outside neurons. The core is surrounded by damaged neuronal extensions, as well as reactive astrocytes and microglia. Abnormal...
Alzheimer Disease l: Introduction01:29

Alzheimer Disease l: Introduction

Alzheimer disease is a chronic, progressive, and irreversible neurodegenerative disorder and the most common cause of dementia in older adults. It leads to gradual neuronal loss, causing cognitive decline, behavioral changes, and loss of functional independence.Risk Factors and EtiologyThe disease is multifactorial. Age is the strongest risk factor, with prevalence doubling every 5 years after age 65. Genetic factors include mutations in genes such as APP, PSEN1, and PSEN2, which are associated...
Dementia l: Introduction01:22

Dementia l: Introduction

Dementia is an acquired, progressive syndrome characterized by a decline in multiple cognitive domains severe enough to impair daily functioning and reduce independence. Although memory loss is a central feature, the diagnosis requires additional deficits involving language, executive function, visuospatial skills, judgment, calculation, or abstract reasoning. These cognitive impairments reflect underlying neurodegenerative or vascular processes that gradually disrupt neuronal networks...
Alzheimer's Disease: Overview01:26

Alzheimer's Disease: Overview

Alzheimer's Disease (AD) is a continually advancing neurodegenerative disorder, distinguished by escalating memory loss, cognitive dysfunction, and dementia. The disease unfolds in three stages: preclinical, mild cognitive impairment (MCI), and dementia. Its onset is insidious, and the progression gradual, with the cause not well explained by other disorders.
The clinical diagnosis of AD hinges on the presence of memory and other cognitive impairments. Biomarkers, such as changes in Aβ and tau...
Hepatic Encephalopathy01:29

Hepatic Encephalopathy

DefinitionHepatic encephalopathy is a reversible neurologic syndrome that results from advanced liver dysfunction or portosystemic shunting. It leads to disturbances in cognition, behavior, and motor function due to the brain’s exposure to gut-derived toxins that the liver fails to detoxify.EtiologyThis condition develops either in the setting of acute fulminant hepatitis or progressively during chronic liver disease, such as cirrhosis and portal hypertension. Portosystemic shunting—including...